在ANCA相关血管炎中实现血清学缓解对后续复发、终末期肾病和死亡风险的影响:一项目标试验模拟研究
该研究利用Mass General Brigham的ANCA相关血管炎观察性队列模拟目标试验,比较诱导治疗后180天内达到血清学缓解(ANCA检测阴性)与未达到者的预后。结果显示,达到血清学缓解与5年内复发风险降低相关(HR 0.55,95%CI 0.38至0.81),但终末期肾病或死亡复合结局无统计学显著差异(HR 0.87,95%CI 0.61至1.25)。
要点
- 诱导后180天内ANCA转阴与5年内复发风险降低相关(HR 0.55,95%CI 0.38至0.81)。
- 血清学缓解与终末期肾病或死亡复合结局无统计学显著差异(HR 0.87,95%CI 0.61至1.25)。
- 5年内81例(16%)死亡、51例(10%)发生终末期肾病、64例(13%)复发。
核心结论
- 在大型ANCA相关血管炎队列模拟的目标试验中,诱导后180天内达到血清学缓解与较低的复发风险相关,但终末期肾病或死亡结局无统计学显著差异。
研究设计与样本
- 利用Mass General Brigham的ANCA相关血管炎观察性队列模拟目标试验,比较诱导后180天内达到与未达到血清学缓解(ANCA检测阴性)的患者。
- 共纳入506例ANCA相关血管炎患者,平均年龄61岁(SD 18),女性占58%,白人占87%,髓过氧化物酶-ANCA阳性占72%,肾脏受累占68%。
- 诱导治疗最常用利妥昔单抗(59%)或环磷酰胺(33%)。
- 采用克隆-删失-加权方法,通过合并logistic回归评估结局。
主要发现
- 5年内81例(16%)死亡,51例(10%)发生终末期肾病,64例(13%)复发。
- 诱导后180天内ANCA检测阴性与复发风险降低相关(HR 0.55,95%CI 0.38至0.81)。
- 诱导后180天内ANCA检测阴性与终末期肾病或死亡复合结局无统计学显著差异(HR 0.87,95%CI 0.61至1.25)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the effect of achieving a negative postinduction antineutrophil cytoplasmic antibody ANCA) assay on the risk of relapse, end-stage renal disease (ESRD) and death in ANCA-associated vasculitis (AAV). METHODS: We emulated a target trial using observational data from the Mass General Brigham AAV cohort comparing patients who achieved versus did not achieve serological remission (negative ANCA assay) within 180 days of induction. Outcomes were relapse, ESRD or death within 5 years, obtained from medical records, the US Renal Data System and the National Death Index. We placed a 'clone' of each patient in both trial arms, censored those deviating from their assigned protocol and weighted each by the inverse probability of censoring. Outcomes were assessed by pooled logistic regression. RESULTS: The study included 506 patients with AAV. The mean age was 61 years (SD 18) and the majority were women (58%), white (87%), myeloperoxidase-ANCA+ (72%) and had renal involvement (68%). Rituximab (59%) or cyclophosphamide (33%) was most often used for induction treatment. Within 5 years, 81 (16%) died, 51 (10%) had ESRD and 64 (13%) had relapse. Patients treated to a negative ANCA assay within 180 days had HR 0.55 (95% CI 0.38 to 0.81) for relapse and HR 0.87 (95% CI 0.61 to 1.25) for the composite of ESRD or death within 5 years. CONCLUSIONS: In this emulated target trial from a large AAV cohort, achieving serological remission within 180 days of induction was associated with lower risk of relapse, but no statistically significant difference in ESRD or mortality outcomes.
引用
- McDermott G, Fu X, Cook C, et al. The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study. Ann Rheum Dis. 2022. PMID: 35697489. doi:10.1136/annrheumdis-2022-222439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。